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PAcute Phosphodiesterase 5 Inhibition
Mimics Hemodynamic Effects of B-Type
Natriuretic Peptide and Potentiates B-Type Natriuretic
Peptide Effects in Failing But Not Normal Canine Heart
Paul R. Forfia, MD, Myung Lee, MS, Richard S. Tunin, MS, Mobusher Mahmud, MD,
Hunter C. Champion, MD, PHD, David A. Kass, MD
Baltimore, Maryland
Objectives The aim of this work was to test whether acute phosphodiesterase 5 (PDE5) inhibition via sildenafil (SIL) mimics
and/or potentiates cardiorenal effects of exogenous natriuretic peptide (NP) infusion.
Background Heart failure (HF) is often accompanied by elevated NP secretion yet blunted responsiveness. Such NP resis-
tance may, in part, relate to increased cyclic guanosine monophosphate (cGMP) catabolism by PDE5.
Methods Dogs (n  7) were studied before and after tachypacing-induced HF. Animals received 30-min infusion of B-type
natriuretic peptide (BNP) (2 g/kg bolus, 0.02 g/kg/min), and on a separate day SIL (1 mg/kg, intravenous),
followed by BNP (SIL  BNP). Phosphodiesterase 5 activity was measured in lung, vasculature, and kidney.
Results At baseline (non-failing), BNP lowered central venous, pulmonary capillary wedge, diastolic, mean pulmonary
artery, and mean arterial pressure. Sildenafil had no effects, and SIL  BNP was similar to BNP alone. In con-
trast, SIL lowered these pressures similarly to BNP in dogs with HF, and SIL  BNP was additive in further reduc-
ing pulmonary pressures over BNP alone. Plasma cGMP/plasma BNP ratio was markedly reduced with HF, indi-
cating NP resistance. Sildenafil plus BNP increased this ratio in HF, but had no effect in non-failing animals.
Sildenafil had no independent diuretic/natriuretic effects nor did it enhance BNP effects under baseline or HF
conditions. In HF, PDE5 activity was significantly increased in the systemic and pulmonary vasculature and in the
kidney.
Conclusions The PDE5 activity in systemic and pulmonary vasculature increases in HF rendering hemodynamic responses to
PDE5 inhibition identical to those from BNP infusion. Natriuretic peptide desensitization in HF relates, in part, to
increased PDE5 activity, supporting a therapeutic role for PDE5 inhibition. (J Am Coll Cardiol 2007;49:
1079–88) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.066i
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ueart failure (HF) is characterized by progressive cardiac
ysfunction often accompanied by pulmonary and systemic
asoconstriction and renal salt and water retention. Activa-
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ion of the endogenous natriuretic peptide (NP) system, and
ubsequent release of atrial natriuretic peptide (ANP) and
-type natriuretic peptide (BNP) is thought to play an
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ccepted August 30, 2006.mportant counter-balancing role against the cardiorenal
equelae of HF (1). However, the net response to endoge-
ous NP is insufficient, and even pharmacologic levels
chieved by exogenous infusion frequently fail to elicit
dequate hemodynamic and/or renal effects, highlighting
rofound NP resistance (2–4).
Natriuretic peptides bind to the natriuretic peptide receptor
ype-A (NPR-A) coupled to particulate guanylate cyclase,
liciting their biologic action by increasing cyclic 3=, 5=-
uanosine monophosphate (cGMP) synthesis. Cyclic
uanosine monophosphate is degraded by phosphodiesterases
uch as PDE5 (5,6). In HF, the ratios of plasma cGMP/
lasma ANP, and urine cGMP/plasma ANP fall markedly,
uggesting impaired cGMP generation despite high NP stim-
lation, consistent with NP resistance (7–9). Up-regulation of
DE5 has been shown to contribute to NP resistance in the
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and other salt retaining states (10–
12). Vascular PDE5 activity is in-
creased in experimental models of
pulmonary hypertension. Since
pulmonary hypertension is often
manifest in HF, a similar increase
in PDE5 could occur and contrib-
ute to NP resistance in HF
(13,14). If so, this would suggest
that PDE5 inhibitors such as sil-
denafil (SIL) might provide equal,
if not greater, hemodynamic ben-
efits as NP agents.
Accordingly, the present study
tested the hypothesis that PDE5
activity is augmented in both
vasculature and kidney in ex-
perimental dilated HF, and that
PDE5 inhibition mimics he-
modynamic and renal effects of
exogenous NP administration
in this condition. We further
determined whether PDE5 in-
ibition enhances cardiovascular-renal actions of exoge-
ous NP.
ethods
urgical preparation. The protocol was approved by the
ohns Hopkins University Animal Care and Use Commit-
ee. Adult mongrel dogs (25 to 30 kg) were chronically
nstrumented for pressure-volume and hemodynamic mon-
toring in the conscious state, as described (15). This
nstrumentation included a micromanometer (P22; Konigs-
urg Instruments, Pasadena, California) placed in the left
entricular (LV) apex to measure pressure, aortic and right
trial catheters for pressure measurements and blood sam-
ling, and endocardial sonomicrometers (Sonometrics
orp., Ontario, Canada) placed to measure anteroposterior,
eptal-lateral, and apex-base dimensions from which LV
olume was derived based on a prolate ellipsoid (16). Right
entricular apical epicardial pacing electrodes were placed to
rovide tachypacing. The dogs were provided 10 to 14 days
o fully recover from surgery before study.
xperimental protocol. Animals were sedated with propofol
0.5 to 2 mg/kg bolus, 0.2 to 0.5 mg/kg every 5 to 10 min), and
balloon-tipped pulmonary artery catheter was inserted
hrough a 7-F right external jugular venous sheath to measure
ulmonary artery pressure and pulmonary capillary wedge
ressure. A Foley catheter was inserted for urine collection.
nimals recovered fully from sedation (60 min), and were
hen allowed to stand freely in a minimally restricting sling for
nother 30 to 60 min before data collection.
Protocol I involved measurements of hemodynamics, blood,
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  B-type natriuretic
peptide
cGMP  cyclic guanosine
monophosphate
dPAP  diastolic
pulmonary artery pressure
HF  heart failure
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
mPAP  mean pulmonary
artery pressure
NP  natriuretic peptide
PDE5  phosphodiesterase
type-5
SIL  sildenafil
SV  stroke volumend urine collection (at 30-min intervals) at baseline and after anfusion of canine BNP-32 (Phoenix Pharmaceuticals, Bel-
ont, California; 2 g/kg bolus, 0.02 g/kg/min  30 min
nto the right atrium). Protocol II utilized the same measure-
ents, with animals first receiving a selective PDE5 inhibitor
lone—SIL (SIL; 1 mg/kg  30 min), followed by the same
NP-32 infusion as Protocol I. At least 48 to 72 h was
rovided between Protocol I and II, with right heart and
rinary catheters removed at the end of each. After animals
ully recovered, they underwent tachypacing at 210 beats/min
4 weeks to induce dilated HF (15), after which the same 2
nfusion protocols were repeated.
ata analysis. Hemodynamic recordings were digitized at
50 Hz. Steady state parameters were assessed at end
xpiration from an average of 10 to 15 sequential beats.
onomicrometer-derived LV volumes were used to derive
troke volume (SV), cardiac output (SV  heart rate), and
eft ventricular ejection fraction (LVEF). In addition, sys-
emic and pulmonary vascular resistance were calculated in
he standard manner, and LV contractile function was
easured based on pre-load-normalized maximal rate of
ressure rise: (dP/dtmax/end-diastolic volume).
lood/urine sample analysis. Blood was collected in tubes
ontaining EDTA (BNP and cGMP) or heparin (SIL), and
mmediately placed on ice. Samples were centrifuged at 2K rpm
or 30 min, plasma separated and stored at 20°C (cGMP and
IL assays) or80°C (BNP assay). Plasma BNPwas determined
y immunoassay Bachem/Peninsula Laboratories, San Carlos,
alifornia) and reported as pg/ml. Plasma and urine cGMPwere
etermined by immunoassay (Amersham Biosciences, Piscat-
way, New Jersey), and reported as pmol/ml. Plasma SIL was
easured by HPLC (SFBC Analytical Laboratories, North
ales, Pennsylvania) reported as ng/ml.
Urine was collected in 50 ml polypropylene tubes and
mmediately placed on ice. Samples were centrifuged at 2K
pm for 30 min, urine separated from sediment and stored
t 20°C until analyzed. Urine sodium concentration was
easured by standard methods, and sodium excretion cal-
ulated as the product of urine flow rate and sodium
oncentration. Urine cGMP excretion was the product of
GMP concentration and urine flow rate. The ratio of
lasma cGMP to plasma BNP (pcGMP/BNP), and urine
GMP to plasma BNP (ucGMP/BNP) were used as in vivo
arkers of NP signaling sensitivity.
issue PDE5 activity assays. The PDE5 activity was
etermined by fluorescence polarization assay (Molecular
evices, Sunnydale, California). Inferior vena cava, whole
ung, pulmonary artery and vein, aorta, and whole kidney
ere obtained from 10 separate dogs: 5 normal dogs, and 5
ogs paced into HF using the identical pacing protocol as
ighlighted in the preceding text. None of these animals
ere subjected to either infusion protocol. Tissue homoge-
ates were prepared from 80°C frozen tissue, with kidney
urther separated into renal glomeruli and inner medullary
ollecting ducts as described (17,18). Total cGMP esterase
ctivity was measured, and the amount of total activity
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March 13, 2007:1079–88 Hemodynamics of PDE5 Inhibition in Canine Heart Failurenhibited by addition of either 0.5 M SIL or 0.1 M
adalafil used to determine activity attributable to PDE5.
tatistical analysis. Data are presented as mean  SEM.
ifferences within and between groups were assessed by 2-way
nalysis of variance with repeated measures. The model in-
luded the physiologic parameter as the dependent variable,
rug treatment (BNP alone, SIL alone, or SIL  BNP), the
og group (control animals vs. HF), and a dummy variable for
ach animal. An interaction term between dog group and drug
reatment served to test for differential responsiveness due to
he presence or absence of HF. A p value 0.05 was consid-
red statistically significant. Differences between non-normally
istributed data (cGMP and BNP) were determined using the
ruskal-Wallis test. Analysis was performed using Systat 10.2
Systat Software, Inc., San Jose, California).
esults
emodynamic response to BNP, SIL, or both in control
nd HF dogs. Representative pressure-volume loop data at
teady-state before and after infusion of BNP, SIL, and
heir combination in both a normal and HF animal are
isplayed in Figure 1. In healthy control animals, BNP
Figure 1 Hemodynamic Effects of BNP, SIL, or Both in Normal an
Representative left ventricular (LV) pressure-volume loops at baseline and after ac
tion of SIL  BNP. Top panels show pressure-volume loops for a non-failing dog (N
Failure).hifted the loop downward to the left, reflecting principally wenodilation (decline in pre-load) with no change in sys-
emic resistance. Sildenafil alone had minimal effects, while
ombined SIL  BNP induced changes similar to BNP
lone. In contrast with control animals, animals with HF
howed very similar cardiac responses to BNP and SIL, each
esulting in chamber unloading: primarily arterial dilation,
long with reductions in LV end-diastolic pressure. The
ombination of both agents appeared to have a modest
dditive effect.
Summary results for both infusion protocols are provided
n Table 1 and Figure 2. At baseline, HF animals had
arkedly reduced contractility (dP/dtmax/end-diastolic vol-
me), LVEF, SV, and increased chamber volumes and LV
nd-diastolic pressure (all p  0.01). There were no
ifferences between baseline hemodynamic values in Proto-
ols I and II; BNP (Protocol I) reduced end-systolic volume
n both normal and HF animals, and decreased pre-load
end-diastolic volume and LV end-diastolic pressure).
troke volume and LVEF rose in failure animals but not
ontrol animals. Contractility was unaltered in either group.
ildenafil alone (Protocol II) had minimal effects on cardio-
ascular hemodynamics in normal dogs. The only changes
ing Hearts Assessed by Cardiac Pressure-Volume Loops
ministration of B-type natriuretic peptide (BNP), sildenafil (SIL), or the combina-
) and the bottom panels for a dog after tachypacing-induced heart failure (Heartd Fail
ute ad
ormalere a small decline in systemic vascular resistance and LV
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ynamic response to BNP and SIL was very similar. Figure
displays this comparison for central venous pressure,
iastolic pulmonary arterial pressure (dPAP), mean pulmo-
ary arterial pressure (mPAP), and mean arterial pressure.
n control animals, all pressures declined with BNP but
ere unaltered by SIL. However, in failing dogs, pressure
eclines in response to BNP alone and SIL alone were
early identical. Moreover, in HF animals, the combination
f SIL  BNP reduced dPAP and mPAP (Fig. 2), as well
s systolic pulmonary (p  0.02) and aortic pressures (p 
.03) to a greater degree than BNP alone, with a trend
emodynamic Data at Baseline, and After BNP, SIL,r SIL  BNP in Dogs efore (Normal) and After Tachypacing-Induc
Table 1 Hemodynamic Data at Baseline, and After BNP, SIL,or SIL  BNP in Dogs Before (Normal) and After Tachy
Protocol I
Baseline BNP
dP/dt/EDV (mm Hg/s/ml)
Normal 30.3 3.6 32.5 3.9
HF 12.3 2.1* 11.7 2.1
LVEF
Normal 0.37 0.01 0.37 0.01
HF 0.20 0.02* 0.22 0.01
EDV (ml)
Normal 91.0 8.6 84.4 7.8§
HF 133.5 12.6 133.0 12.5
ESV (ml)
Normal 57.6 5.7 52.9 5.0§
HF 108.0 11.7* 103.9 10.7
HR (beats/min)
Normal 100 7 106 11
HF 127 4* 116 7
SV (ml)
Normal 33.5 3.2 31.5 2.9
HF 25.5 1.9 29.1 2.1§
CO (l/min)
Normal 3.3 0.2 3.2 0.3
HF 3.2 0.3 3.4 0.3
LVSP (mm Hg)
Normal 133.6 4.4 119.0 3.3
HF 108.4 3.8* 102.4 4.1
PVR (dyne·sec·cm5)
Normal 221 23 206 19
HF 142 29 125 8.8
SVR (dyne·sec·cm5)
Normal 2,703 248 2,544 264
HF 2,286 264 2,062 274
PCWP (mm Hg)
Normal 5.6 0.9 3.9 0.8†
HF 18.8 1.9* 14.7 1.5§
LVEDP (mm Hg)
Normal 6.5 0.9 4.1 1.0‡
HF 28.0 2.6* 23.9 2.4‡
emodynamic data in normal and failing (HF) dogs at baseline and after acute administration of
p  0.01 and p  0.05 comparing baseline values of normal dogs to baseline values of HF dog
F animals; ¶p  0.05 for the interaction between drug treatment and HF.
CO  cardiac output; EDV  end-diastolic volume; ESV  end-systolic volume; HR  heart rat
entricular systolic pressure; PCWP  pulmonary capillary wedge pressure; PVR  pulmonary vasoward further reductions in mean arterial pressure (p  a.08), and LV end-diastolic pressure (p  0.08). The
eductions in dPAP and mPAP, as well as heart rate, in HF
nimals treated with SIL were greater than those reported in
ormal dogs, indicating a differential hemodynamic respon-
iveness of the failing dog to acute PDE5 inhibition. B-type
atriuretic peptide, however, did not demonstrate this
ifferential effect, as it exerted similar hemodynamic actions
n normal and failing dogs. Reductions in dPAP and mPAP
n response to SIL  BNP were also greater in HF animals
han in normal control animals (p  0.003 and p  0.06,
espectively).
Pulmonary vascular resistance declined with SIL in HF
F
g-Induced HF
Protocol II
SIL  BNPBaseline SIL
30.9 3.6 32.3 3.9 31.7 3.5
12.2 1.7 11.5 1.5 11.3 1.6
0.40 0.01 0.40 0.02 0.39 0.02
0.21 0.01 0.23 0.01‡ 0.24 0.01‡
92.7 8.5 90.2 8.5 86.7 8.0‡
131.1 11.9 131.2 11.9 131.6 11.8
56.0 5.8 54.7 5.8 52.9 5.2†
103.9 10.6 101.2 10.0† 100.1 10.2*
95 6 111 10 104 8
129 5 123 4¶ 115 6†¶
36.7 3.1 35.5 3.1 33.8 3.3†
27.2 2.0 30.0 2.5† 31.5 2.1‡
3.4 0.2 3.9 0.4 3.5 0.3
3.5 0.3 3.7 0.3 3.6 0.3
129.0 3.8 126.0 1.9 111 3.1
109.1 4.2 101.1 3.5 95.6 3.0
194 22 167 28 193 23
182 36 106 29§ 111 8§
2,493 232 2,158 223§ 2,174 274§
2,056 169 1,786 196§ 1,734 180§
6.4 1.0 5.4 1.2 3.1 0.8†
17.3 1.2 13.0 1.4† 11.6 1.0‡
7.5 1.0 4.8 1.3‡ 1.6 0.7‡
25.1 1.8 19.4 0.8* 18.6 1.0‡
natriuretic peptide (BNP), sildenafil (SIL), or the combination of SIL  BNP.
0.01, ‡p  0.001, and §p  0.05 comparing treatment values to baseline values in normal and
P  left ventricular end-diastolic pressure; LVEF  left ventricular ejection fraction; LVSP  left
sistance; SV  stroke volume; SVR  systemic vascular resistance.ed H
pacin
†
§
§
B-type
s; †p nimals, whereas BNP had no significant effect (Fig. 3).
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March 13, 2007:1079–88 Hemodynamics of PDE5 Inhibition in Canine Heart Failureulmonary vascular resistance declined similarly with SIL
NP as with SIL alone, supporting the primary influence of
IL. Neither agent significantly changed pulmonary vascu-
ar resistance in non-failing controls.
ascular and renal PDE5 activity. Figure 4A shows
ummary results for PDE5 activity from various vascular
issues in both control and HF animals. Enzyme activity
ose significantly in whole lung, pulmonary artery, aorta,
nd inferior vena cava from HF animals versus control
nimals. This change is consistent with the amplified
asodilatory effects of PDE5 inhibition in these vascular
eds in HF animals. Renal PDE5 activity (Fig. 4B) also
Figure 2 Baseline and Differential Change in Venous, Pulmonary,
Bar graphs illustrating the acute change in hemodynamics to B-type natriuretic pep
failure dogs (right). *p  0.05 versus baseline; †p  0.05 comparing SIL  BNP
failure. CVP  central venous pressure; dPAP  diastolic pulmonary arterial pressncreased as measured in whole kidney and inner medullary eollecting ducts. The PDE5 activity in isolated glomeruli
as not significantly altered, although total cGMP esterase
ctivity was increased 31% (p  0.03, not shown).
lasma BNP, cGMP, and pcGMP/BNP ratios. Figures
A to 5C display results for plasma BNP and cGMP levels and
heir ratio in both normal and HF dogs. In normal dogs, BNP
nfusion raised plasma BNP nearly 4-fold over baseline, and
ncreased plasma cGMP by 36.2  12.7 pmol/ml (p 
.05). Sildenafil plus BNP did not alter the pcGMP/BNP over
aseline or BNP alone, indicating proportional increases in
lasma cGMP in relation to BNP in the non-failing circula-
ion. However, in HF, basal plasma BNP was markedly
rterial Pressures to BNP, SIL, or Both in Normal and Failing Heart
NP), sildenafil (SIL), or the combination of SIL  BNP in normal (left) and heart
s BNP alone; #p  0.05 for the interaction between drug treatment and heart
AP  mean arterial pressure; mPAP  mean pulmonary arterial pressure.and A
tide (B
versu
ure; Mlevated whereas plasma cGMP was only modestly increased
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Hemodynamics of PDE5 Inhibition in Canine Heart Failure March 13, 2007:1079–88ver non-failure controls. As a result, the pcGMP/BNP ratio
eclined substantially (p  0.0001), consistent with NP de-
ensitization. B-type natriuretic peptide infusion alone did not
urther elevate plasma BNP or cGMP. However, plasma
GMP rose substantially with SIL alone, and more so with
IL  BNP; both responses were significantly above BNP
lone (Fig 5B). The paired disparity between cGMP change
ith SIL versus BNP was far greater in HF than non-failing
nimals (p  0.025). Combined SIL  BNP raised plasma
GMP 6- to 7-fold despite a trend toward declining BNP
evels by the end of the infusion (p  0.15), increasing the
cGMP/BNP ratio.
nfluence of BNP, SIL, and both combined on renal
unction. B-type natriuretic peptide increased urine flow
ate (0.75  0.18 ml/min to 2.2  0.52 ml/min; p  0.05)
nd sodium excretion (104.2  39.3 Eq/min to 245.6 
7.3 Eq/min; p  0.05) in normal dogs (Fig. 6). In
ontrast, SIL had neither diuretic nor natriuretic effects,
hile SIL  BNP induced changes similar to BNP alone.
n HF dogs, the renal response to BNP was blunted
ompared with controls, with both urine flow and sodium
xcretion change reaching borderline significance (p 
.09). Sildenafil did not alter either parameter, and
ombined SIL  BNP resulted in similar responses to
NP alone. Renal PDE5 activity was increased in whole
idney and inner medullary collecting ducts, but did not
each significance in isolated glomeruli (Fig. 4, lower
anels).
Basal urine cGMP concentration and urine cGMP pro-
uction (data not shown) were not elevated in HF, and did
ot change with BNP, although they trended to rise with
IL  BNP (p  0.06). The ucGMP/BNP ratio was
educed in HF animals at baseline, was not significantly
ltered by BNP alone, but did rise modestly with SIL 
Figure 3 Greater Decline in PVR by SIL  BNP in Animals
With Heart Failure Versus Control Animals
Bar graphs showing the change in pulmonary vascular resistance (PVR) in
response to B-type natriuretic peptide (BNP), sildenafil (SIL), or the combination
of SIL  BNP in non-failing (normal; solid bars) and failing (heart failure;
hatched bars) dogs. *p  0.05 versus baseline values.NP (p  0.01 vs. baseline).iscussion
his study demonstrates that acute administration of the
elective PDE5 inhibitor SIL is as effective in unloading the
ailing heart as a moderate dose of exogenous BNP, whereas in
ontrast with BNP, SIL has little hemodynamic impact on
ormal animals. Moreover, SIL enhanced the hemodynamic
ffects of BNP, particularly within the pulmonary circulation of
Figure 4 PDE5 Activity in Vascular and Renal Beds
of Control and Heart Failure Animals
Bar graphs illustrating the percentage of total phoshodiesterase activity that is
attributable to cyclic guanosine monophosphate-specific type 5 phosphodiester-
ase (PDE5) in vascular (A) and renal (B) tissue obtained from non-failing (nor-
mal) and failing (heart failure) dogs. *p  0.05 versus values in normal dogs.
cGMP  cyclic guanosine monophosphate; IMCD  inner medullary collecting
ducts; IVC  inferior vena cava.
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March 13, 2007:1079–88 Hemodynamics of PDE5 Inhibition in Canine Heart Failureailing animals. Importantly, PDE5 activity significantly in-
reased in the vasculature of HF relative to non-failing animals,
uggesting a mechanism underlying enhanced hemodynamic
esponsiveness to SIL in HF. Renal PDE5 activity also
ncreased with HF; however, SIL alone produced no diuretic
r natriuretic effects, and the renal effects of SIL plus BNP
ere not additive to BNP alone. The data further support a
ole of PDE5 up-regulation as a contributor to NP desensiti-
ation, and suggest potential utility of combined treatment to
aximize the hemodynamic benefits of endogenous or exog-
nous BNP.
In light of the vasodilatory and natriuretic actions of
NP and BNP, it was initially hypothesized that HF
epresented a state of NP deficiency. However, investigators
bserved that patients with elevated cardiac filling pressures
nd clinical HF had markedly elevated ANP and BNP
evels, instead implying that HF is a state of NP resistance
19,20). This was supported by depressed pcGMP/BNP
atios (7,8), particularly as plasma and urine cGMP levels
elate primarily to NP-derived, particulate guanylate
yclase-generated cGMP, rather than nitric oxide-derived,
oluble guanylate cyclase-generated cGMP (2,21). Others
ound marked blunting of ANP- and BNP-mediated fore-
rm vasodilation and impaired vascular cGMP production
n HF patients (2,3), and marked increases in the molar
atio of ANP extraction to cGMP production in pulmonary
nd systemic vasculature of HF patients versus control
Figure 5 BNP, cGMP, and Their Ratio in Plasma and Urine in A
Bar graphs showing the B-type natriuretic peptide (BNP) concentration (A), plasma
plasma BNP (C), urine cGMP concentration (D), and ratio of urine cGMP to plasm
response to acute administration of BNP, sildenafil (SIL) (B only), and the combin
 0.03, ¶p  0.005: between group (congestive heart failure [CHF] vs. normal) foatients (8,22). Diuretic and natriuretic responses to endog- anous and exogenous NP and renal cGMP generation are
lso blunted in experimental and clinical HF (4,9,23).
Natriuretic peptide desensitization and decreased cGMP
eneration in the vasculature and kidney in HF can have
everal causes including NPR-A receptor down-regulation,
p-regulation of NP clearance receptors, neurohormonal coun-
erregulation, and increased cGMP catabolism— principally
y up-regulation of PDE5 (24). The activity of PDE5 has
een found to increase in isolated glomeruli from failing
anines, inner medullary collecting ducts of pregnant rats, and
ats with a bile duct ligation model of cirrhosis, suggesting a
ole for PDE5 up-regulation in renal NP resistance for HF and
ther salt-retaining states (11,12,17). In addition, pulmonary
ascular PDE5 activity increases in experimental pulmonary
ypertension (13,14). Alternatively, a recent study showed that
espite markedly increased plasma BNP levels determined by
mmuno-fluorescence assay in patients with HF, mass spec-
rometry did not reveal any BNP-32, the biologically active
orm of BNP (25). This raises the question as to whether
ltered forms of BNP may contribute to NP resistance in
linical HF. It remains unclear whether this paradigm applies
o canine HF. However, our finding that SIL induced cardiac
nloading along with substantial increases in plasma cGMP
uggests that circulating BNP in our failing dogs was biolog-
cally active.
We observed increased pulmonary and systemic vascular
DE5 activity in experimental HF, compared with control
ls With Normal or Failing Hearts
guanosine monophosphate (cGMP) concentration (B), ratio of plasma cGMP to
(E) of normal (solid bars) and failing dogs (hatched bars) at baseline and in
f SIL  BNP. *p  0.03, #p  0.06: within group comparison to baseline; †p
e intervention; ‡p  0.04: within group, versus BNP alone.nima
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his setting. The PDE5 up-regulation was not isolated to the
ulmonary vascular bed, suggesting that the stimulus, such as
levated circulating NP or counterregulatory neurohormones,
as diffuse. Despite this, BNP and SIL exerted similar hemo-
ynamic actions in HF animals, with the exception of pulmo-
ary vascular resistance, that only declined with SIL. This
ndicates that NP resistance was more marked in the pulmo-
ary vasculature, requiring PDE5 inhibition to yield vasodila-
or effects from BNP. This was further supported by the
nding that SIL  BNP produced additive effects in the
ulmonary circulation. Importantly, these changes did not
ccur with untoward reductions in systemic arterial pressure.
hus, the hemodynamic actions of acute PDE5 inhibition in
he current study, either alone or combined with BNP,
rincipally targeted sites with abundant PDE5 activity, such as
he lung (26).
The physiologic significance of an interaction between
DE5 inhibition and circulating BNP was revealed by
ifferential hemodynamic effects of SIL in HF versus
ormal dogs. In line with these observations, the relative
ncrease in plasma cGMP in response to SIL was far greater
n failing than non-failing animals, indicating that PDE5
nhibition enhanced endogenous NP signaling preferentially
n HF. Moreover, the hemodynamic responses to exogenous
NP were enhanced through acute PDE5 inhibition, with
marked rise in the pcGMP/BNP ratio when SIL and
Figure 6 Urinary Flow and Sodium Excretion in Animals With N
Bar graphs demonstrating the effects of B-type natriuretic peptide (BNP), sildenafil
flow rate and urine sodium excretion of normal (left; solid bars) and heart failure dNP were combined. In contrast, SIL  BNP did not firoduce additive hemodynamic effects, elevate plasma
GMP levels, or alter the pcGMP/BNP ratio in non-failing
nimals despite increased circulating BNP levels after BNP
nfusion. This is consistent with the relatively low levels of
ascular PDE5 activity in normal control animals. These
esults imply that a significant degree of the differential
ascular responsiveness between HF and control animals
ccurs via post-NPR-A receptor modulation of NP signal-
ng (i.e., at the level of PDE5).
Circulating BNP levels significantly rose with exogenous
NP in normal but not in failing dogs. This contrasts to
rior animal and human studies have reported increased
irculating BNP after its infusion in HF (27–30). One
otential explanation is that the infused BNP lowered
ardiac load reducing endogenous release and offsetting the
hange due to the infusion itself. Heart failure animals had
ery high basal BNP, so withdrawal could potentially have
uch an effect. This was supported by the SIL  BNP data,
here unloading in HF dogs was even greater, and net BNP
hanges trended to a decline. In a prior canine study, basal
entricular dilatation and BNP were far below that in the
urrent experiments, and less decline in endogenous release
ight explain a greater rise with exogenous infusion (27).
Another potential explanation for this difference lies in
he half-life of BNP, which is only 1.5 min in the dog
31). We administered BNP as a bolus followed by intra-
enous infusion; thus, 80% of the dose was delivered in the
l or Failing Hearts in Response to BNP, SIL, or Both Combined
or the combination of SIL  BNP on urine
right; hatched bars). *p  0.05 versus baseline.orma
(SIL),
ogs (rst minute of the 30-min period. Yet, biological effects of
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onger t1/2 of cGMP (30 min in the dog) (31,32). The t1/2
or BNP is 22 min in humans, which could also explain
ome differences to clinical studies. A phase-lag between
NP and cGMP levels could have artificially increased the
cGMP/BNP ratio with SIL  BNP in HF dogs. How-
ver, it could not explain baseline changes, the relative
mpairment of endogenous NP signaling in HF, nor marked
isparity in cGMP response to BNP versus BNP  SIL.
hough BNP was not assessed when SIL was administered
lone, the latter also raised cGMP substantially, while likely
owering BNP due to hemodynamic unloading (in HF), so
he pcGMP/BNP ratio would have increased.
Potentiating effects between SIL and BNP are concor-
ant with recent data obtained in rats with hypoxic pulmo-
ary hypertension, which found that SIL pre-treatment
ugmented pulmonary vasodilation and increased plasma
GMP levels with ANP infusion over ANP alone (33).
oreover, NPR-A receptor deficiency impairs pulmonary
asodilating effects of SIL or SIL ANP in murine models
f hypoxic pulmonary hypertension (34,35). We also found
hat SIL influenced hemodynamics only in the setting of
igh intrinsic NP, suggesting such activity may be impor-
ant to enhancing the hemodynamic efficacy of PDE5
nhibitors.
Similar to the pcGMP/BNP ratio, the ucGMP/BNP
atio also declined in HF versus normal dogs, supporting
mpairment of in vivo renal NP signaling. While SIL 
NP also elevated this ratio, it was due less to increased
rinary cGMP than to reduced plasma BNP. Thus, PDE5
ensitization in the kidney was not as robust as in the
asculature in this model, a conclusion further supported by
he lack of significant diuretic-natriuretic effects with SIL in
he HF animals. This result is somewhat different to prior
tudies employing zaprinast to block PDE5, which induced
rapid natriuresis in a rat arterio-venous fistula model of
F, or natriuresis and greater urinary cGMP production
hen infused directly in the renal artery in canine HF
9,23). Differences between these prior data and the current
tudy may relate to the model and/or mode of drug
dministration (intravenous, which also lowered blood pres-
ure, versus intrarenal), and less specificity of zaprinast for
DE5 (17,36). Neurohormonal counterregulation may also
lay a role, as acute angiotensin-converting enzyme inhibi-
ion and angiotensin II blockade both enhance renal respon-
iveness to ANP (37,38).
The plasma SIL level achieved in our protocol was 413
g/ml, comparable to that measured in humans after a
ingle 50-mg dose (39). This raises an intriguing possibility
hat acute PDE5 inhibition might provide an alternative
pproach to treat acutely decompensated HF, potentially
voiding the expense and inconvenience of intravenous NP.
he inhibition of PDE5 alone or combined with BNP may
e particularly efficacious in patients with the combination
f advanced HF and pulmonary hypertension, and in
articular those with reduced pcGMP/NP ratios, as thisould suggest PDE5 up-regulation with greater NP desen-
itization (26). Chronic background PDE5 inhibition may
lso enhance endogenous NP responsiveness, but this re-
ains to be demonstrated. Lastly, in pulmonary arterial
ypertension, where NP levels are often normal or only
odestly elevated, administration of BNP has recently
hown to amplify the pulmonary vasodilatory effects of SIL
herapy, supporting our findings (40–42).
The present study has several limitations. A relatively
mall sample size may have led to underestimation of more
ubtle hemodynamic effects of BNP, SIL, or their combi-
ation. Moreover, a greater sample size might have revealed
ffects on urine flow rate and sodium excretion, although the
ata did not even suggest a trend in this regard, whereas the
emodynamic effects were quite significant. We used a
ingle dose of both SIL and BNP, and it remains possible
hat varying dosage combinations might better optimize (or
orsen) their pharmacologic interaction. This may again be
elevant to the renal data, where perhaps lower doses of SIL
nd/or BNP without any blood pressure changes may have
ad more effect on diuresis and natriuresis. In addition, we
id not perform the experimental protocols in random
rder, which could potentially introduce bias. However, the
baselines were nearly identical suggesting such bias was
nlikely. Lastly, we examined acute effects of SIL, more by
ay of a comparison with current clinical uses of BNP.
uture studies are needed to determine if chronic PDE5
nhibition has additional benefit by reducing NP resistance
nd restoring intrinsic NP responsiveness.
Since its clinical introduction in 2001, administration of
NP has become integrated into the treatment of acutely
ecompensated HF (43). While originally tested for its
apacity to benefit hemodynamics, current use is often
imed at assisting in diuresis of diuretic refractory patients.
owever, the treatment is costly, requires intravenous
nfusion, and recent meta-analysis has questioned the over-
ll safety/efficacy profile and, in particular, potential involve-
ent of BNP in renal complications (44,45). Our finding
hat an oral alternative such as SIL yields identical or better
emodynamic effects compared with clinically relevant BNP
osing suggests an intriguing alternative approach. Use of
he pcGMP/BNP ratio may help identify individuals with a
igh degree of NP desensitization most likely to benefit
rom this approach or from combined PDE5 inhibition and
ow-dose BNP. Human studies are needed, but the current
ata help pave the way for such investigations.
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